Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Manometry | 1 | 2013 | 43 | 0.470 |
Why?
|
| Esophageal Achalasia | 1 | 2013 | 57 | 0.440 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 212 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2022 | 386 | 0.320 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 737 | 0.270 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2023 | 7 | 0.230 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2023 | 24 | 0.220 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 335 | 0.200 |
Why?
|
| Ethanol | 2 | 2023 | 249 | 0.200 |
Why?
|
| Oxadiazoles | 1 | 2021 | 32 | 0.200 |
Why?
|
| Indans | 1 | 2021 | 31 | 0.200 |
Why?
|
| Colonic Polyps | 1 | 2022 | 126 | 0.200 |
Why?
|
| Arteriosclerosis | 2 | 2002 | 112 | 0.200 |
Why?
|
| Intensive Care Units | 2 | 2021 | 374 | 0.190 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 60 | 0.190 |
Why?
|
| Pneumonia | 1 | 2022 | 179 | 0.190 |
Why?
|
| Central Nervous System Depressants | 1 | 2000 | 45 | 0.180 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 63 | 0.180 |
Why?
|
| Lipoproteins | 1 | 2000 | 136 | 0.180 |
Why?
|
| Aortic Diseases | 1 | 2000 | 96 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2022 | 359 | 0.180 |
Why?
|
| Cholesterol | 1 | 2000 | 353 | 0.160 |
Why?
|
| Microbiota | 1 | 2023 | 382 | 0.150 |
Why?
|
| Oxygen | 1 | 2021 | 724 | 0.140 |
Why?
|
| Hospitalization | 1 | 2021 | 830 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 937 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 711 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1749 | 0.120 |
Why?
|
| Electric Impedance | 1 | 2013 | 104 | 0.110 |
Why?
|
| Liver | 3 | 2023 | 1229 | 0.110 |
Why?
|
| Aged | 6 | 2022 | 18161 | 0.110 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2011 | 26 | 0.100 |
Why?
|
| Gastrectomy | 1 | 2011 | 68 | 0.100 |
Why?
|
| Nutritional Status | 1 | 2011 | 83 | 0.100 |
Why?
|
| Duodenum | 1 | 2011 | 101 | 0.100 |
Why?
|
| Stomach | 1 | 2011 | 108 | 0.090 |
Why?
|
| Humans | 11 | 2023 | 85778 | 0.080 |
Why?
|
| Male | 6 | 2022 | 40652 | 0.070 |
Why?
|
| Female | 6 | 2022 | 44216 | 0.050 |
Why?
|
| Macrophage-1 Antigen | 1 | 2002 | 17 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 73 | 0.050 |
Why?
|
| Aspartate Aminotransferases | 1 | 2022 | 72 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 79 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 8456 | 0.050 |
Why?
|
| Bradycardia | 1 | 2021 | 39 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 69 | 0.050 |
Why?
|
| Serbia | 1 | 2021 | 2 | 0.050 |
Why?
|
| Serum Albumin, Human | 1 | 2021 | 5 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 180 | 0.050 |
Why?
|
| Maintenance Chemotherapy | 1 | 2021 | 76 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 28 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 164 | 0.050 |
Why?
|
| Monocytes | 1 | 2002 | 216 | 0.050 |
Why?
|
| Diet, Atherogenic | 1 | 2000 | 15 | 0.050 |
Why?
|
| Middle Aged | 4 | 2022 | 24740 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2021 | 147 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6479 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2022 | 267 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2000 | 93 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 277 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 230 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2021 | 257 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 299 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 295 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 25518 | 0.040 |
Why?
|
| Aging | 1 | 2022 | 689 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 371 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 704 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 1458 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1696 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 922 | 0.040 |
Why?
|
| Hypertension | 1 | 2021 | 703 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1776 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2213 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2000 | 3111 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 5249 | 0.030 |
Why?
|
| Digestion | 1 | 2011 | 7 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2011 | 128 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 302 | 0.020 |
Why?
|
| Mice | 2 | 2002 | 11438 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 451 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 7830 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 266 | 0.020 |
Why?
|
| Animals | 2 | 2002 | 26650 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3591 | 0.020 |
Why?
|
| Quality of Life | 1 | 2011 | 1581 | 0.010 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2002 | 15 | 0.010 |
Why?
|
| Integrins | 1 | 2002 | 76 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2002 | 129 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2002 | 424 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 738 | 0.010 |
Why?
|
| Protein Binding | 1 | 2002 | 1462 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 1760 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 1944 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2240 | 0.010 |
Why?
|